admin

University of Maryland Received a 2013 NIH Grant for $219,084 for Age-Related Changes in Renal Morphology and Function in Chronic Kidney Disease. The principal investigator is Yu Chen. The program begain in 2012 and ends in 2014. Below is a summary of the proposed work.

This application is in response to PA-09-166 “Renal Function and Chronic Kidney Disease (CKD) in Aging (R21)”. CKD is a growing problem among the aging population. According to the United States Renal Data System, the number of older patients with end-stage renal disease (ESRD) has almost doubled over the last 25 years.

I don’t think I’ve ever (in 20+ years of writing) reprinted a press release verbatim. Often I don’t even get to the end of them because of all the PR speak. However, today the Mayo Clinic sent out this list. It is concise, compelling and I can’t think of any way to improve it. The 10 ways the human genome map can affect diagnosis and treatment is an important reminder that we have come a long way in a short time, and that healthcare in the United States is not all about arguing about who gets care and who pays for it.

In case you had any doubts that the $3.8 billion investment in the genome mapping project was worth it, consider these 10 advancements compiled by the Mayo Clinic.

United Therapeutics Corporation announced today that the U.S. Food and Drug Administration (FDA) has acknowledged the resubmission of the new drug application (NDA) for treprostinil diolamine extended release tablets (oral treprostinil) for the treatment of pulmonary arterial hypertension. The FDA classified the resubmission as a complete, class 2 response to its March 22, 2013 complete response letter, and set a user fee goal date of February 16, 2014.

About United TherapeuticsUnited Therapeutics Corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions.

Normal adult cells have been reprogrammed to become stem cells inside live mice for the first time.

As stem cells can be coaxed into developing into almost any kind of cell, being able to prompt this behaviour in the body could one day be used to repair ailing organs including the heart, liver, spinal cord and pancreas.

“By doing it in situ, the cells are already there in the tissue, in the right position,” says Manuel Serrano at the Spanish National Cancer Research Centre in Madrid, and co-leader of the new work.

The University of Maryland and Northrop Grumman will jointly announce the launch of the Advanced Cybersecurity Experience for Students (ACES), the nation’s first cybersecurity honors program for undergraduates, at a special event on Wednesday, September 25, 2013, from 10:30-11:30 a.m. in the Stamp Student Union Atrium on the University of Maryland College Park Campus.

The ACES program is designed to educate future leaders in the field of cybersecurity through rigorous, hands-on learning experiences, an intensive interdisciplinary curriculum, collaborative projects, and professional insight from industry and business leaders. The four-year honors program offers students a living-learning experience, giving them the opportunity to collaborate and work closely together as they pursue their advanced program of study in cybersecurity. The inaugural ACES cohort is comprised of 57 students. The ACES program is supported by a major grant from Northrop Grumman. For more information about the program, visit aces.umd.edu.

The INNo program trains research scientists in the entrepreneurial skills needed to bring technology inventions and services to the healthcare market.

Participants in the INNo program learn to:

• Identify and evaluate the commercial potential of intellectual property
• Understand the business fundamentals related to technology start-ups
• Create a value proposition and business concept for a new product, platform, or service
• Articulate investment opportunities persuasively to potential investors and partners
• Develop a network of resources in the Maryland entrepreneurial community

Roche’s move to skip over Inovio’s (NYSE: INO) late stage drugs for cervical cancer and Hepatitis C and make a beeline for its preclinical DNA vaccines for prostate cancer and Hep B was initially a little puzzling. Investors have preferred to park their money further upstream when products are in the clinic and they’ve been derisked. Big pharma is always looking for ways to take costs out of research and development. But the prospect of utilizing new technology with the potential to improve treatment is appealing for drug developers that want to build up and strengthen their drug pipeline.